F1‐02‐02: NFκB and Complement C3 Mediated Neuron‐glia Interaction in Neuronal Health and Alzheimer's Disease

Hui Zheng
DOI: https://doi.org/10.1016/j.jalz.2015.07.011
2015-01-01
Abstract:Abnormal NFκB activation has been implicated in Alzheimer's disease (AD). However, the signaling pathways governing NFκB regulation and function in the brain are poorly understood. Here we examined the cell-specific effects and signaling pathways of NFκB activation in the brain and their impact in AD pathogenesis. Taking advantage of the principal inhibitory role of IκBa in NFκB regulation, we used Cre-directed IκBα deletion to create mice in which NFκB was selectively activated in either neurons or astroglia and combined the genetic model with neuron-astrocyte co-cultures to study the mechanisms of aberrant NFκB signaling in vitro and in vivo. We further tested the relevance of this pathway in AD by performing biochemical and functional analysis in AD mouse models. We identify complement protein C3 as an astroglial target of NFκB, and show that C3 release acts through neuronal C3aR to disrupt dendritic morphology and network function. Exposure to Ab activates astroglial NFκB and C3 release, consistent with the high levels of C3 expression in brain tissue from AD patients and APP transgenic mice, where C3aR antagonist treatment rescues cognitive impairment. Our studies reveal a critical role for the astroglial NFκB and C3 in neuronal homeostasis. Dysregulation of neuron-glia interaction through NFκB/C3/C3aR signaling may contribute to synaptic dysfunction in AD and C3aR antagonists may be therapeutically beneficial.
What problem does this paper attempt to address?